DV
Dividend Vision

FDMT — 4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc (FDMT)

Total return is -69.9% over the past 5.7 years, 199.1 points behind SPY at 129.2%. Its deepest 1-year drawdown was 41.4%.

4D Molecular Therapeutics is a late-stage biotechnology company developing gene therapy treatments based on adeno-associated virus vectors, with its lead candidate 4D-150 targeting retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema, and a pipeline of earlier-stage programs for conditions including cystic fibrosis and alpha-1 anti-trypsin deficiency. The company does not currently distribute dividends. This security appeals to investors seeking exposure to clinical-stage biotechnology development rather than current income.

FDMT key facts

Asset type
Stock
Asset class
Equity
Inception date
12/11/2020
Last close
$12.19
Market cap
$574,516,032
Average volume
773700.0
Beta
2.691
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.57